BIOGEN INC.
Known title: 10% OwnerCIK: 0000875045
Associated companies
Transaction History
| BIIB | ▼ Sell | Open Market | 6,000,000 | $3.0M | 9/26/2023 | View on chart |
| BIIB | ▼ Sell | Open Market | 100,000 | $527K | 8/30/2022 | View on chart |
| BIIB | ▼ Sell | Open Market | 400,000 | $2.1M | 8/29/2022 | View on chart |
| BIIB | ▼ Sell | Open Market | 2,764 | $24K | 12/28/2021 | View on chart |
| BIIB | ▼ Sell | Open Market | 600 | $5K | 12/27/2021 | View on chart |
| BIIB | ▼ Sell | Open Market | 81,187 | $695K | 12/23/2021 | View on chart |
| BIIB | ▼ Sell | Open Market | 23,660 | $203K | 12/9/2021 | View on chart |
| BIIB | ▼ Sell | Open Market | 75,814 | $655K | 12/8/2021 | View on chart |
| BIIB | ▼ Sell | Open Market | 52,178 | $444K | 12/7/2021 | View on chart |
| BIIB | ▼ Sell | Open Market | 1,874 | $16K | 12/2/2021 | View on chart |
| BIIB | ▼ Sell | Open Market | 730 | $6K | 12/1/2021 | View on chart |
| BIIB | ▼ Sell | Open Market | 28,884 | $248K | 11/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade
Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.